Differential dysregulation of granule subsets in WASH-deficient neutrophil leukocytes resulting in inflammation

Johnson et al. Supplementary Information



FAM21-MPO



Supplementary Figure 1 FAM21 localizes at azurophilic granules

Immunofluorescence analysis of the colocalization of endogenous FAM21 at MPO-positive puncta in WT and *Wash*-cKO *Washc1^{haemo}* neutrophils. Colocalization shown in white. Lower panel, Colocalization coefficient, mean \pm SEM. 24 WT and 23 *Wash*-cKO analyzed from 3 independent mice. Scale bar = 3 µm. ****, p<0.0001. Two-tailed unpaired Student's t-test.



Wild type and *Wash*-cKO *Washc1*^{haemo} neutrophils present similar levels of expression of azurophilic granule cargoes and gelatinase granule cargoes

Flow cytometry analysis of total elastase and MMP-9 expression in permeabilized cells. n=3 independent mice. Mean ± SD. ns, not significant. Two-tailed Mann-Whitney test.



Analysis of the vesicular dynamics of neutrophil granules expressing EGFP-LAMP3, analyzed at the exocytosis active zone using TIRF microscopy

Analysis complementary to Figure 2i. Analysis of vesicular dynamics of neutrophil granules expressing EGFP-LAMP3, analyzed at the exocytosis active zone using TIRF microscopy. The speeds for the independent vesicles were binned in 0.1 μ m/s increments and plotted as a percentage of total vesicles for a given cell. Results are represented as mean ± SEM from 20 WT cells and 12 *Wash*-cKO cells from two independent experiments displaying numbers of non-motile (docked) and motile azurophilic granules in wild-type and *Wash*-cKO cells.





Effect of the Arp2/3 inhibitor CK666 on azurophilic granule exocytosis

A, Wild-type and *Wash*-cKO (*Washc1*^{△haemo}) neutrophils were treated with CK666 (50µM) or vehicle for 1 hour and subsequently stimulated with fMLF (F). Where indicated, the cells were primed with GM-CSF before stimulation (G/F). n=12 independent mice analyzed in four independent experiments. Mean ± SEM. The compared groups are indicated with brackets in the

figure. Two-tailed paired t-test across samples and conditions (NS, F, and G/F). The analysis to compare unstimulated and stimulated conditions within each group were performed by one-tailed paired t-test and indicated with asterisks; *, p<0.05; **, p<0.01; ****, p<0.0001; ns, not significant. B-D, Analysis of the effect of CK666 on the localization of Arp2 and azurophilic granule (elastase) related to F-actin (phalloidin). Cells were treated with 50 or 150 μ M CK666 (indicated in the x-axis) or vehicle. B-D, The colocalization between F-actin (phalloidin)-Arp2 (B); F-actin and the azurophilic granule marker elastase (C) and Arp2-elastase (D) was analyzed by Airyscan enhance resolution fluorescent confocal microscopy. At least 40 cells from 3 independent mice were analyzed per condition. B-D, The data are represented as mean ± SEM. One-way ANOVA Tukey's multiple comparison test. ***, p=0.0002; ****, p<0.0001; ns, not significant. E, Representative Airyscan images and colocalization analysis of Arp2-F-actin whose quantification is presented in (B). At least 40 cells from 3 independent mice were analyzed per condition.



JFC1- MPO

Supplementary Figure 5

Increased recruitment of the Rab27a-effector JFC1 at azurophilic granules in Washdeficiency

Immunofluorescence analysis of the recruitment of endogenous JFC1 at azurophilic granules (MPO) in wild-type and *Wash*-cKO neutrophils that were either left unstimulated or stimulated with cytochalasin D and fMLF (CytD/F). Mean ± SEM. Each symbol represents an independent cell measurement. A total of 59 unstimulated WT cells, 62 unstimulated *Wash*-cKO cells, 60 stimulated WT cells and 54 stimulated *Wash*-cKO cells were analyzed in 3 independent experiments. ****, p<0.0001, two-tailed unpaired t-test.



Analysis of the basal secretion of Specific granules in Wash-cKO neutrophils

The concentration of the Specific granule cargoes NGAL and lactoferrin (LTF) secreted from unstimulated WT and *Wash-cKOWashc1^{haemo}*) neutrophil was determined by ELISA. Mean ± SEM (n=3 independent mice). ns, not significant. Two-tailed Mann-Whitney test.



Azurophilic granule exocytosis is increased by anti-WASH inhibitory antibodies

Human neutrophils were permeabilized using SLO and incubated in the presence of anti-WASH inhibitory antibodies or IgG control as described under Methods. Exocytosis of azurophilic granules was monitored by the upregulation of the marker CD63 (LAMP3) at the plasma membrane by flow cytometry analysis. n=3 independent donors. Mean \pm SEM. *, p=0.025, Two-tailed unpaired Student's t-test.



Activation of Rac1 by CID888706 (ML-099) using a Rac1 biosensor

Mouse embryonic fibroblasts were transfected with the Rac1-2G biosensor (mTFP-PBD-Venus-Rac1)¹. Forty-eight hours after transfection, the cells were treated with the Rac1 activator CID888706 (CID)² (10 μ M) or vehicle for 1 hour, fixed and analyzed using Airyscan enhance resolution fluorescent confocal microscopy. Quantification of FRET signal was performed using the Airyscan integrated FRET module in a Zeiss LSM 880 laser scanning confocal microscope. A, Representative images and magnifications of CID-treated and untreated cells. B, Mean ± SEM of the Relative FRET intensity in CID-treated and untreated cells. Twelve CID-treated and 12 cells untreated cells from seven independent fields were included in the analysis. ***, p=0.0006. Two-tailed Mann-Whitney test.

MMP9



Supplementary Figure 9

The Arp2/3 inhibitor CK666 does not inhibit Gelatinase granule exocytosis

Wild type and *Wash*-cKO (*Washc1^{haemo}*) neutrophils were treated with CK666 (50 µM) or vehicle for 1 hour and subsequently stimulated with fMLF (F) and gelatinase (MMP-9) in the supernatants was analyzed by ELISA. Where indicated, the cells were primed with GM-CSF before stimulation (G/F). A, n=12 independent mice analyzed in two independent experiments. Mean \pm SEM. ****, WT vs *Wash*-cKO: p=2.9x10⁻¹¹, for both CK666 (p=7.6x10⁻⁶) and vehicle (p=7.6x10⁻⁶) and all each stimulated group within (all p=0.03). CK666 positive *vs* vehicle: p=2.1x10⁻⁶. True for both WT (p=3.3x10⁻⁴) and *Wash*-cKO (p=4.0x10⁻³). Two-tailed Wilcoxon signed rank test. B, Comparative analysis of the effects of 50 and 150 µM CK666 on MMP9 secretion. Experiments were performed as in A, except neutrophils were pre-incubated with vehicle or either 50 or 150 µM CK666 before stimulation. No significant differences were observed between treatments with 50 or 150 µM CK-666, two-tailed paired t-test across samples and conditions (NS, F, and G/F), n=6 independent mice. Mean \pm SEM. **, p<0.01 between the indicated CK666 condition and its vehicle control in each group (WT or *Wash*-cKO).



Wash-cKO neutrophils present altered cell spreading

a. Analysis of actin (green) remodeling in wild-type and *Wash*-cKO neutrophils expressing YFPactin, by TIRFM. The red lines represent the growth maps of laminar actin profiles at the indicated time of analysis. The magnified images show that actin remodeling is significantly more active in WT cells. b. Quantification of the cell spreading based on actin labeled growth map as a function of time. The dynamics of YFP-actin remodeling was continuously monitored over the 30 sec in WT (blue symbols) and *Wash*-cKO (red symbols) neutrophils. Each time point on the plot represents the average area increase (%) from n=32 WT and 12 *Wash*-cKO neutrophils analyzed in 2 independent experiments. Mean ± SEM.



WT

Supplementary Figure 11

Hematology analysis of wild-type and Wash-cKO (Washc1^{haemo} mice

Quantification of the absolute number of the indicated WBC was performed as detailed under Methods. Mean \pm SEM, n=3 independent mice; *, p= 0.0293. Two-tailed, unpaired Student's t-test.



Supplementary Figure 12 Inflammatory profile of unchallenged *Wash-*cKO (*Washc1^{haemo}*) mice

The plasma levels of the indicated cytokines were determined using Multiplex technology (Millipore). Mean ± SEM. n=4 independent mice. All analyses: not significant, two-tailed unpaired Student's t-test.



Supplementary Figure 13 Characterization of the *Wash*^{fl/fl}/*Mrp8-Cre+* mouse model

a, Mice that were genotyped by Transnetyx technology, were further validated for *Cre* integration using the following primers: oIMR1084 (Cre F); oIMR1085 (Cre R); oIMR7338 (internal control F); oIMR7339 (Internal control R) (The Jacksons Laboratory), which produce the expected fragments of ~100 bp (Transgene, *Cre*-specific band) and 324 bp (Internal positive control). fl/fl indicates

Wash^{fl/fl}. n=3. **b**, Flow cytometry analysis of GFP (*Mrp8-Cre*-ires/GFP) expression in mature neutrophils isolated from the indicated mouse model by positive selection (Ly6G+). **c**, Western blot analysis of WASH expression in isolated Ly6G+ neutrophils. Upper panel, representative immunoblots of 3 independent mice. Lower panel, quantification of 3 independent experiments. Mean \pm SEM, *, p=0.0236, two-tailed unpaired t-test. **d**, Analysis of plasma MPO in *Wash*^{fl/fl}-*Mrp8*-*Cre*+ and *Wash*^{fl/fl}-*Mrp8*-*Cre*- neutrophils. n=9. Mean \pm SEM. *, p=0.0351 two-tailed unpaired Student's t-test. **e**, Analysis of plasma MMP-9 in *Wash*^{fl/fl}-*Mrp8*-*Cre*+ and *Wash*^{fl/fl}-*Mrp8*-*Cre*- neutrophils. n=6. Mean \pm SEM. ns, not significant. Two-tailed Student's t-test. **f**, Quantitative analysis of neutrophil counts in blood. n=11, 3 independent experiments. Mean \pm SEM. ns, not significant with or without outlier (#). Two-tailed unpaired Student's t-test. **g**, Analysis of azurophilic granule exocytosis in isolated unstimulated neutrophils measured as the secreted myeloperoxidase (MPO). n=3 independent mice. Mean \pm SEM.**, p=0.0084, two-tailed Student's t-test. **h**, Analysis of gelatinase granule exocytosis in isolated unstimulated neutrophils measured as the secreted student's t-test. **h** Student's t-test.

а

Azurophilic granule

Cytosol Rab27a Actin MPO FAM21 Arp2/3 WASH b

Gelatinase granule



Supplementary Figure 14

Schematic models showing differential control of neutrophil granule subtype exocytosis by WASH

a. Dual role of WASH in the regulation of azurophilic granule exocytosis. WASH interferes with the binding of the small GTPase Rab27a to its effector molecule JFC1 inhibiting docking and preventing unwanted secretion. Actin entrapment of azurophilic granules mediated by WASH contributes to the repression of azurophilic granule exocytosis in an Arp2/3-dependent manner. **b.** Role of WASH in the regulation of gelatinase granule exocytosis. WASH contributes to the formation of actin comets that help position gelatinase granules in the exocytic actin zone. Rac1 localization at gelatinase granule requires WASH. In the absence of WASH, FAM21 accumulates at gelatinase granules while Rac1 recruitment is defective leading to impaired actin comet formation, and defective trafficking and exocytosis of gelatinase granules. Adapted with permission from Reference ³.



Supplementary Figure 15 Original immunoblots from Supplementary Figure 13c

S14c



Flow cytometry gating strategies for neutrophils and their precursors

a. Gating strategy for mouse mature neutrophils after isolation by positive selection. **b.** Gating strategy for human mature neutrophils after isolation. **c.** Automated single-cell analysis of healthy mouse BM cells using conventional flow cytometry identifies the neutrophil mature, immature and progenitor populations. Figure exemplifying the gating strategy for the identification and sorting of mature and immature neutrophils. (NeP, committed unipotent early-stage neutrophil progenitor).

Supplementary Table 1 Mass spectrometry analysis of the neutrophil secretome (Gelatinase/Specific granules)



Mass spectrometry analysis of gelatinase/secondary granule secretome

Proteins identified in the secretome of both WT and Wash-cKO

Proteins identified in the secretome of Wash-cKO but not WT

Proteins identified in the secretome of WT but not Wash-cKO

Mass spectrometry analysis of the secretome of wild-type and *Wash-c*KO *Washc1^{haemo}*) neutrophils treated with fMLF that favors Gelatinase/Specific granule secretion over azurophilic granule secretion. Grey, proteins detected in both WT and *Wash-c*KO neutrophils secretory supernatant; Red, proteins identified in WT but not in *Wash-c*KO neutrophil supernatants; Blue, proteins identified in *Wash-c*KO neutrophils but not in WT neutrophil's supernatants. 3 independent mice. See associated Supplementary Data 1 and 2.

Supplementary Table 2. Reagents, Vendors and Catalogue numbers

| Reagent | Vendor | Catalogue Number | Working dilution (if applicable) |
|--|--------------------------|------------------|----------------------------------|
| Lv6G MicroBeads UltraPure | Miltenvi Biotec Inc | 130-120-337 | |
| Lv6G MicroBead Kit (discontinued) | Miltenvi Biotec Inc | 130-092-332 | |
| LS Columns | Miltenvi Biotec Inc | 130-042-401 | |
| MACS smart strainers | Miltenvi Biotec Inc | 130-110-915 | |
| Alexa Fluor 488 Phalloidin | ThermoFisher Scientific | A12379 | |
| Alexa Fluor 568 Phalloidin | ThermoFisher Scientific | A12380 | |
| Alexa Fluor 594 Phalloidin | ThermoFisher Scientific | A12381 | |
| Alexa Fluor 647 Phalloidin | ThermoFisher Scientific | A22287 | |
| Atto-488 anti-mouse | ThermoFisher Scientific | 41051 | 1.400 |
| Alexa Eluor 488 goat anti-mouse | ThermoFisher Scientific | Δ32723 | 1:400 |
| Alexa Fluor 488 goat anti-rabbit | ThermoFisher Scientific | A-11029 | 1:400 |
| Alexa Fluor 568 donkey anti-rabbit | ThermoFisher Scientific | A100/2 | 1:400 |
| Alexa Fluor 568 donkey anti-rabbit | ThermoFisher Scientific | Δ11057 | 1:400 |
| Alexa Fluer 568 donkey anti-goat | ThermoFisher Scientific | A10037 | 1:400 |
| Alexa Fluor 500 donkey anti-mouse | | A10037 | 1:400 |
| Alexa Fluer 647 denkey anti-goat | | A2 1447 | 1:400 |
| Alexa Fluor 647 donkey anti-mouse | | A-31371 | 1:400 |
| Alexa Fluor 647 donkey anti-tabbit | | A31373 | 1.400 |
| Alexa Fluor 647 goat anti-rat | Life Technologies | AZ1Z47 | 1:400 |
| Anti-CD63 (LAMP3) (NVG-2) Fluor 647 | Biolegena | 143921 | 1:50 |
| Anti-CD11b (clone M1/70) Fluor 647 | BD Biosciences | 557686 | 1:50 |
| Anti-Ly6G (clone 1A8) | BD Biosciences | 127610 | 1:50 |
| Anti-neutrophil elastase | Abcam | Ab68672 | 1:50 |
| Anti-Rac1 | Proteintech | 24072-1-AP | 1:1000 |
| Anti-Rac1-GTP | NewEast Biosciences | 26903 | 1:100 |
| Anti-RhoA | Santa Cruz Biotechnology | SC-418 | 1:1000 |
| Anti-Rab21 | Novus Biologicals | NBP1-81544 | 1:200 |
| Anti-Lamp1 | Santa Cruz Biotechnology | sc-19992 | 1:200 |
| Anti-Arp2 | Abcam | ab49674 | 1:200 |
| Anti-mouse-Ly6G-FITC (clone 1A8) | Tonbo | 35-1276 | 1:50 |
| Anti-mouse MPO clone 8F4 | HycultBiotech | HM1051-100UG | 1:200 |
| Anti-MPO | R&D | AF3667 | 1:400 |
| Anti-mouse MMP-9 | R&D | AF909 | 1:1000 |
| Terbium-conjugated anti-Myc Antibody | Cisbio US Inc | 61MYCTAB | 1:1000 |
| Anti-mCherry | Abcam | ab213511 | 1:1000 |
| Mouse MPO Duoset ELISA | R&D Systems | DY3667 | |
| Mouse MMP-9 Duoset ELISA | R&D Systems | DY6718 | |
| Cytochalasin D | Enzo Life Sciences | BMLT1090001 | |
| N-Formyl-Met-Leu-Phe (fMLF) | Sigma-Aldrich | F3506 | |
| LPS from E. coli, Serotype O111:B4 (TLRGRAD) | Enzo Life Sciences | ALX-581-012-L002 | |
| | | | |
| Recombinant Mouse GM-CSF | Shenandoah Biotechnology | 200-15-20UG | |
| Rac1 activator (CID888706 MI -099) | Cayman Chemical | 15176 | |
| Arp2/3 inhibitor CK666 | Sigma-Aldrich | SMI 0006 | |
| PhoA inhibitor (C3 Transferase) | Cytoskeleton | | |
| CXCI 1 Protein mouse recombinant | Sino Biological | 50150-MNCE | |
| over i rotein, mouse recombinant | Cillo Diological | SO ISO-MINOL | |
| CXCL2 Protein mouse recombinant | Sino Biological | 50070-M08Y | |
| Hypodermic Needle 30G 0.5" | Fisher Scientific | 1484102 | |
| Plastinak 3-Piece Luer-Lok Syringes | BD Biosciences | 300912 | |
| RPMI 1640 Medium, no phenol red | Life Technologies | 11835-030 | |
| Fetal Bovine Serum | | 10.082-147 | |
| Bolt Bis-Tris Plus gale () | | | |
| Nitrocellulose membranos | GVS Filter Technology | 1 215 / 9/ | |
| SuperSignal West Disc | Thormo scientific | 1,213,404 | |
| SuperSignal West Pico | | 34,300 | |
| Revent 700 Total Protein Stain | | 103,540-314 | |
| | | 15,710 | |
| Fluoromount-G reagent | SouthernBiotech | 0100–01 | |
| Mercaptoethanolamine | Sigma-Aldrich | M3148 | |
| Glucose oxidase | Sigma-Aldrich | G2133-250KU | |
| 4-chamber 35-mm glass-bottom dish | In Vitro Scientific | D35 C4-20-1.5-N | |

Supplementary Table 3. All antibodies used in CyTOF and their conjugated labels

| | HSPC Line | age | Μ | lyeloid Lin | eage | Lymph | oid/Erythr | oid Lineage | Hetero | geneity (r | nigration) |
|---------|--------------|-------------|---------|-------------|-------------|---------|-------------|--------------|---------|------------|-------------|
| Isotope | Metal | Specificity | Isotope | Metal | Specificity | Isotope | Metal | Specificity | Isotope | Metal | Specificity |
| 89 | Y | CD45 | 142 | Nd | CD11c | 115 | In | CD41 | 144 | Nd | CXCR4 |
| 146 | Nd | CD43 | 148 | Nd | CD11b | 115 | In | Ter119 | 154 | Sm | CXCR2 |
| 151 | Eu | CD16/32 | 159 | Tb | CD169 | 115 | In | CD127 | 164 | Dy | CXCR3 |
| 156 | Gd | CD48 | 159 | Tb | CD64 | 115 | In | CD3 | | | |
| 158 | Gd | CD34 | 159 | Tb | CD68 | 153 | Eu | CD335 | Hete | rogeneity | (other) |
| 166 | Er | CD117 | 159 | Tb | F4/80 | 147 | Sm | CD105 | Isotone | Motal | Specificity |
| 167 | Er | CD150 | 160 | Gd | CD115 | 176 | Yb | B220 | 150 | Nd | CD24 |
| 169 | Tm | Sca1 | 161 | Dy | SiglecF | Hete | rogeneity (| function) | 162 | Dv | |
| | NA -1 | | 163 | Dy | FceRla | | Malal | C : [i . : i | 102 | Dy Ex | CDZOL |
| | Maturati | on | | | | Isotope | Ivietai | Specificity | 168 | Er | CD79b |
| Isotope | Metal | Specificity | Hetero | geneity (a | ictivation) | 143 | Nd | GPR-32 | 170 | Er | CD35 |
| 141 | Pr | CD101 | Isotope | Metal | Specificity | 165 | Но | VEGFR2 | 171 | Yb | LFA-1 |
| 145 | Nd | Ly6G | 149 | Sm | 62L | 173 | Yb | TLR4 | 172 | Yb | CD38 |
| 155 | Gd | Ly6B | 152 | Sm | CD162 | 174 | Yb | MHCII | 175 | Lu | CD16.2 |

Supplementary Table 4. Antibodies used for CyTOF and dilution factors

| Model Metal College Metal Collugate Manual college Dubbase Dubbase <thdubbase< th=""> <thdubbase< th=""> Dubbas</thdubbase<></thdubbase<> |
|---|
| CD43 D311 D401 Huidigm DV3 400 CD43 S11 146Nd Fluidigm DV5 600 CD16/32 93 151Eu Biolegend In-house 100 CD48 HM48.1 156Gd Fluidigm DVS 400 CD34 MEC14.7 158Gd Biolegend In-house 100 CD17 288 166Er Fluidigm DVS 100 CD100 TC1512F12.2 167Er Fluidigm DVS 400 CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD140 307707 141Pr Invitrogen In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 4 |
| CD45 J11 Linku Linku <thlin< td=""></thlin<> |
| CD10/32 33 1110 Biolegend Influse 100 CD48 HM48.1 156Gd Fluidigm DVS 400 CD34 MEC14.7 158Gd Biolegend In-house 100 CD17 288 166Er Fluidigm DVS 100 CD150 TC1512F12.2 167Er Fluidigm DVS 400 CD101 307707 141Pr Invitigm DVS 400 CD101 307707 141Pr Invitigm DVS 400 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly68 7/4 155Gd abcam In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD169 306.112 159Tb Biolegend In-house 400 CD44 X54-5/7.1 159Tb Biolegend In-house 100 F4/80 BM8 159Tb Fluidigm DVS 400 |
| CD48 Inives.1 15050 Private 100 CD34 MEC14.7 1586d Biolegend In-house 100 CD17 288 166Er Fluidigm DVS 100 CD150 TC1512F12.2 167Er Fluidigm DVS 100 Ly-6A/E D7 169Tm Fluidigm DVS 400 CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly66 1A8 142Nd Fluidigm DVS 400 CD11c N418 142Nd Fluidigm DVS 400 CD14b M1/70 148Nd Fluidigm DVS 400 CD64 X54-5/7.1 159Tb Biolegend In-house 200 F4/80 BM8 159Tb Fluidigm DVS 400 CD155 AF598 160Gd Biolegend In-house 100 <t< td=""></t<> |
| CD34 INECULA.7 IS880 Bluegend Initiality Intervence Initiality CD117 288 166Er Fluidigm DVS 100 CD150 TC1512F12.2 167Er Fluidigm DVS 400 Ly-6A/E D7 169Tm Fluidigm DVS 400 CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD11b M1/70 148Nd Fluidigm DVS 400 CD11b M1/70 148Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 400 CD64 X54-5/7.1 159Tb Biolegend In-house 100 Siglec F E50-2440 (RU0) 161Dy BD Biosciences In-house 100 FceRla Mar-1 163Dy |
| CD117 288 166Fr Fluidigm DVS 100 CD150 TC1512F12.2 167Er Fluidigm DVS 100 Ly-6A/E D7 169Tm Fluidigm DVS 400 CD101 307707 141Pr Invitogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly6B 7/4 155Gd abcam In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 400 CD64 X54-5/7.1 159Tb Biolegend In-house 200 F4/80 BM8 159Tb Fluidigm DVS 400 CD115 AFS98 160Gd Biolegend In-house 100 Siglec F E50-2440 (RUO) 161Dy BD Biosciences In-house 400 CD162 MRA10 152Sm BD Biosciences |
| CD150 ICLS12F12.2 I6/Fr Fluidigm DVS 100 Ly-6A/E D7 169Tm Fluidigm DVS 400 CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly6B 7/4 155Gd abcam In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD11c N418 142Nd Fluidigm DVS 400 CD11b M1/70 148Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 200 F4/80 BM8 159Tb Fluidigm DVS 400 CD115 AFS98 160Gd Biolegend In-house 100 Siglec F E50-2440 (RUO) 161Dy BD Biosciences In-house 400 CD62L MEL-14 149Sm Biolegend In-ho |
| Ly-6A/E D/ Ib9/Im Fluidigm DVs 400 CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD11b M1/70 148Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 400 CD64 X54-5/7.1 159Tb Fluidigm DVS 400 CD115 AFS98 160Gd Biolegend In-house 100 Siglec F E50-2440 (RUO) 161Dy BD Biosciences In-house 400 CD62L MEI-14 149Sm Biolegend In-house 400 CD62L MEL-14 149Sm Biolegend |
| CD101 307707 141Pr Invitrogen In-house 100 Ly-6G 1A8 145Nd Biolegend In-house 100 Ly6B 7/4 155Gd abcam In-house 400 CD11c N418 142Nd Fluidigm DVS 400 CD11b M1/70 148Nd Fluidigm DVS 400 CD169 3D6.112 159Tb Biolegend In-house 400 CD64 X54-5/7.1 159Tb Biolegend In-house 200 F4/80 BM8 159Tb Fluidigm DVS 400 CD115 AFS98 160Gd Biolegend In-house 100 Siglec F E50-2440 (RUO) 161Dy BD Biosciences In-house 400 CD62L ME1-14 149Sm Biolegend In-house 400 CD62L ME1-14 149Sm Biolegend In-house 800 CD162 4RA10 152Sm BD Biosciences |
| Ly-6G1A8145NdBiolegendIn-house100Ly6B7/4155GdabcamIn-house400CD11cN418142NdFluidigmDVS400CD11bM1/70148NdFluidigmDVS400CD1693D6.112159TbBiolegendIn-house400CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house400CD62LMEI-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house400CD33529A1.4153EuBD BiosciencesIn-house100 |
| Ly6B7/4155GdabcamIn-house400CD11cN418142NdFluidigmDVS400CD11bM1/70148NdFluidigmDVS400CD1693D6.112159TbBiolegendIn-house400CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| CD11cN418142NdFluidigmDVS400CD11bM1/70148NdFluidigmDVS400CD1693D6.112159TbBiolegendIn-house400CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house800CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3329A1.4153EuBD BiosciencesIn-house100 |
| CD11bM1/70148NdFluidigmDVS400CD1693D6.112159TbBiolegendIn-house400CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD62LMEL-14152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| CD1693D6.112159TbBiolegendIn-house400CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| CD64X54-5/7.1159TbBiolegendIn-house200F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| F4/80BM8159TbFluidigmDVS400CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| CD115AFS98160GdBiolegendIn-house100Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD35529A1.4153EuBD BiosciencesIn-house100 |
| Siglec FE50-2440 (RUO)161DyBD BiosciencesIn-house100FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| FceRlaMar-1163DyBiolegendIn-house400CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD3529A1.4153EuBD BiosciencesIn-house100 |
| CD62LMEL-14149SmBiolegendIn-house400CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| CD1624RA10152SmBD BiosciencesIn-house400CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| CD41MWReg30115InBiolegendIn-house800Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| Ter119TER-119115InBiolegendIn-house800CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| CD127A7R34115InBiolegendIn-house400CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| CD3145-2C11115InBiolegendIn-house100CD33529A1.4153EuBD BiosciencesIn-house100 |
| CD335 29A1.4 153Eu BD Biosciences In-house 100 |
| |
| CD105 MJ7/18 147Sm Biolegend In-house 400 |
| B220 RA36B2 176Yb Fluidigm DVS 400 |
| GPR-32 Polyclonal 143Nd Abcam In-house 10 |
| CD309 (VEGFR2) 89B3A5 165Ho Biolegend In-house 10 |
| TLR4 MTS510 173Yb Biolegend In-house 100 |
| MHC class II M5/114.15.2 174Yb Fluidigm DVS 400 |
| CD184(CXCR4) L276F12 144Nd Biolegend In-house 10 |
| CD182(CXCR2) SA044G4 154Sm Biolegend In-house 100 |
| CD183 (CXCR3) CXCR3-173 164Dv Biolegend In-house 400 |
| CD24 M1/69 150Nd Fluidigm DVS 200 |
| Lv-6C HK14 162Dv Biolegend In-house 400 |
| CD79b HM79-12 168Er Biolegend In-house 100 |
| CD35 11-5/CRTAM 170Er Biolegend In-house 200 |
| CD11a (LEA-1) M17/4 171Yb Biolegend In-house 200 |
| CD38 90 172Yb Biolegend In-house 200 |
| CD16.2 9F9 175Lu Biolegend In-house 200 |

References

- 1. Fritz, R.D. *et al.* SrGAP2-Dependent Integration of Membrane Geometry and Slit-Robo-Repulsive Cues Regulates Fibroblast Contact Inhibition of Locomotion. *Dev Cell* **35**, 78-92 (2015).
- 2. Palsuledesai, C.C. *et al.* Activation of Rho Family GTPases by Small Molecules. *ACS Chem Biol* **13**, 1514-1524 (2018).
- 3. Johnson, J.L. *et al.* Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation: DRUGGABILITY OF THE SMALL GTPase Rab27a. *The Journal of biological chemistry* **291**, 25965-25982 (2016).